Search clinical trials for: Gefitinib

Total 408 results

AstraZeneca

Completed

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Advanced Tumor

Netherlands
Pfizer

Completed

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

ALK-positive NSCLC

Sweden
Sun Yat-sen University

Unknown

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC (FL-ALTER)

Lung Cancer, Nonsmall Cell

China
Eli Lilly and Company

Completed

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Lymphoma | Carcinoma, Non-Small-Cell Lung | Solid Tumors

Japan
European Organisation for Research and Treatment...
AstraZeneca

Active, not recruiting

Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) (APPLE)

NSCLC

France, Spain, Slovenia, Jordan, Poland
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

Esophageal Cancer

United States
National University Hospital, Singapore
National Healthcare Group, Singapore

Completed

A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839

Nasopharyngeal Carcinoma

Singapore
Pfizer

Completed

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Italy, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
Daiichi Sankyo Co., Ltd.

Terminated

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Taipei Veterans General Hospital, Taiwan

Completed

UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer

Non-Small-Cell Lung Cancer

Taiwan
Weill Medical College of Cornell University

Terminated

Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer

Head and Neck Cancer

United States
University of Chicago

Completed

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

Head and Neck Cancer

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Non Small Cell Lung Cancer

China
Yonsei University

Unknown

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

Completely Resected NSCLC With Common EGFR Mutations

Korea, Republic of
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma

United States
Massachusetts General Hospital
National Cancer Institute (NCI); Dana-Farber Cancer Institute; AstraZeneca; Brigham...

Completed

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Head and Neck Cancer

United States
Betta Pharmaceuticals Co., Ltd.

Completed

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients (ICOGEN)

Non-small Cell Lung Cancer

China
MedImmune LLC
AstraZeneca

Completed

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Carcinoma, Non-Small-Cell Lung

United States, Korea, Republic of, Japan
Gachon University Gil Medical Center

Unknown

Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC

Non-Small Cell Lung Cancer

Korea, Republic of
Fudan University

Unknown

Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy

Carcinoma, Non-Small-Cell Lung

China
AstraZeneca

Completed

Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer

Metastatic Breast Cancer

Norway
University of Alabama at Birmingham
National Cancer Institute (NCI)

Completed

Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Lung Cancer

United States
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; AstraZeneca; Kentuckiana...

Completed

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Nonresectable Adrenocortical Carcinoma

United States
Alpha Biopharma (Jiangsu) Co., Ltd.

Completed

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (BM)

Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

China, Korea, Republic of, Singapore, Taiwan
M.D. Anderson Cancer Center
GlaxoSmithKline; AstraZeneca

Completed

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States
AstraZeneca

Completed

Iressa Versus Docetaxel (Taxotere)

Non-Small-Cell Lung Carcinoma

United States, Croatia, Sweden, Italy, Mexico, Spain, Turkey, Germany, Philippines, Malaysia, China, Estonia, Latvia, Hong Kong, Argentina, Belgium, Canada, Denmark, France, Indonesia, Thailand, Brazil, Switzerland, Singapore, Slovenia
National Cancer Institute (NCI)

Completed

Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
Sun Yat-sen University

Recruiting

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

China
AstraZeneca

Completed

ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer

Breast Cancer

France
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Non-Small-Cell Lung Cancer
Shanghai University of Traditional Chinese Medicine
Shanghai Chest Hospital

Unknown

Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma

Cancer
National Cancer Institute (NCI)

Completed

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
Stanford University
National Cancer Institute (NCI)

Completed

Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

Colorectal Cancer

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI); Norris Cotton Cancer Center

Completed

Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer

Breast Cancer

United States
National Cancer Center, Korea
AstraZeneca

Completed

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

Lung Cancer

Korea, Republic of
Peking Union Medical College Hospital

Unknown

Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC

Non-small Cell Lung Cancer

China
Beta Pharma Shanghai

Active, not recruiting

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

NSCLC

China
London School of Hygiene and Tropical Medicine

Completed

Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2) (NECTAR2)

Malaria, Falciparum

Mali
Benaroya Research Institute
Sanofi; AstraZeneca

Completed

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

Prostate Cancer

United States
AstraZeneca

Completed

Iressa as Second Line Therapy in Advanced NSCLC-Asia (ISTANA)

NSCLC

Korea, Republic of
Massachusetts General Hospital
Novartis

Active, not recruiting

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...

Completed

Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

Metastatic Pancreatic Carcinoma

United States
AstraZeneca

Completed

Phase II Iressa Versus Vinorelbine (INVITE)

Non-Small-Cell Lung Carcinoma

Czech Republic, Italy, Korea, Republic of, South Africa, United Kingdom, Germany, Australia, Taiwan, France, Brazil
Stanford University

Withdrawn

Botulinum Toxin Injection for Functional Popliteal Artery Entrapment Syndrome

Popliteal Artery Entrapment Syndrome | Functional Popliteal Artery Entrapment Syndrome

United States
Roswell Park Cancer Institute

Completed

Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of Texas Southwestern Medical Center
Novartis

Withdrawn

Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

Metastatic Anaplastic Thyroid Cancer | Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer

United States
Shandong University
The Affiliated Hospital of Qingdao University; Qianfoshan Hospital; The Second...

Recruiting

Antineoplastic Drugs in Elderly Patients

Cancer

China
Tang-Du Hospital

Unknown

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

Lung Neoplasms

China

Search clinical trials for: Gefitinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations